psilocybin has been researched along with ketamine in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.13) | 18.7374 |
| 1990's | 1 (2.56) | 18.2507 |
| 2000's | 3 (7.69) | 29.6817 |
| 2010's | 11 (28.21) | 24.3611 |
| 2020's | 22 (56.41) | 2.80 |
| Authors | Studies |
|---|---|
| Henriksson, BG; Järbe, TU | 1 |
| Cohen, S | 1 |
| Vollenweider, FX | 1 |
| Koller, R; Schmid, L; Umbricht, D; Vollenweider, FX | 1 |
| Cuddy, ML | 1 |
| Hunt, N; McCambridge, J; Mitcheson, L; Winstock, A | 1 |
| Gamma, A; Studerus, E; Vollenweider, FX | 1 |
| Bachmann, R; Kometer, M; Schmidt, A; Seifritz, E; Vollenweider, F | 1 |
| Young, SN | 1 |
| Brugger, S; Carhart-Harris, RL; Nutt, DJ; Stone, JM | 1 |
| Borschmann, R; Kaar, S; Winstock, AR | 1 |
| Florova, G; Girard, RB; Idell, RD; Idell, S; Komissarov, AA; Shetty, S | 1 |
| Barrett, AB; Carhart-Harris, RL; Muthukumaraswamy, SD; Schartner, MM; Seth, AK | 1 |
| Horsley, RR; Kolin, J; Páleníček, T; Valeš, K | 1 |
| Heifets, BD; Malenka, RC | 1 |
| Carhart-Harris, R; Muthukumaraswamy, S; Nutt, D; Pallavicini, C; Tagliazucchi, E; Vilas, MG; Villarreal, M; Zamberlan, F | 1 |
| Nutt, D | 1 |
| Barnett, L; Carhart-Harris, RL; Muthukumaraswamy, SD; Seth, AK | 1 |
| Bottemanne, H; Claret, A; Fossati, P | 1 |
| Aguilar-Valles, A; De Gregorio, D; Gobbi, G; Heifets, BD; Hibicke, M; Mitchell, J; Preller, KH | 1 |
| Courault, P; Demarquay, G; Lancelot, S; Zimmer, L | 1 |
| Bates, MLS; Trujillo, KA | 1 |
| Baker, G; Dos Santos, RG; Dursun, S; Hallak, JE | 1 |
| Forsyth, A; Lumley, T; Muthukumaraswamy, SD | 1 |
| Bugno, R; Golebiowska, J; Hogendorf, A; Khoo, SY; Malikowska-Racia, N; Nikiforuk, A; Popik, P; Zajdel, P | 1 |
| Bysiek, A; Gołembiowska, K; Herian, M; Maćkowiak, M; Majcher-Maślanka, I; Szych, Z; Wawrzczak-Bargiela, A; Wojtas, A | 1 |
| Berens, N; Kim, SY | 1 |
| Davis, AK; Deiparine, S; Gao, T; Levin, A; Mitchell, J; Nagib, PB | 1 |
| Dycha, N; Kurzepa, J; Nowak, EM; Psiuk, D; Samardakiewicz, M; Łopuszańska, U | 1 |
| Bláhová, B; Chomynová, P; Kňažek, F; Kočárová, R; Mravčík, V; Plevková, M; Valeš, K | 1 |
| Davoudian, PA; Kwan, AC; Shao, LX | 1 |
| Ibi, D | 1 |
| Jha, MK; Kamal, S; Radhakrishnan, R | 1 |
| Chakrabarty, T; DuBois, A; Keramatian, K; Saraf, G; Yatham, LN | 1 |
| Chen, J; Chen, T; Cheng, L; Liu, H; Liu, Z; Ma, J; Pi, C; Shen, H; Tang, J; Wei, Y; Xiong, L; Yuan, J; Zhang, X; Zhao, L; Zhong, Y; Zuo, Y | 1 |
| Ibrahim, IB; Straszek, SPV; Videbech, P | 1 |
| Basbaum, A; Corder, G; Dworkin, RH; Edwards, RR; Eickhoff, CR; Eickhoff, SB; Larsen, B; Linguiti, S; McKinstry-Wu, A; Pines, A; Roalf, DR; Satterthwaite, TD; Scott, JC; Sharma, V; Strain, EC; Sydnor, VJ; Vogel, JW; Wellman, N | 1 |
| Chruścicka-Smaga, B; Machaczka, A; Pilc, A; Szewczyk, B | 1 |
| Wojtas, A | 1 |
17 review(s) available for psilocybin and ketamine
| Article | Year |
|---|---|
Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.
Topics: Anesthetics, Dissociative; Brain; Consciousness; Dopamine; Glutamic Acid; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Psilocybin; Serotonin | 1998 |
Common drugs of abuse--Part II.
Topics: 4-Butyrolactone; Catha; Designer Drugs; Dibenzothiazepines; Diterpenes; Diterpenes, Clerodane; DOM 2,5-Dimethoxy-4-Methylamphetamine; Drug and Narcotic Control; Flunitrazepam; Hallucinogens; Humans; Illicit Drugs; Ketamine; Lysergic Acid Diethylamide; Methamphetamine; Motivation; N-Methyl-3,4-methylenedioxyamphetamine; Phencyclidine; Phenylpropanolamine; Piperazines; Psilocybin; Quetiapine Fumarate; Sodium Oxybate; Substance-Related Disorders; United States | 2004 |
Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.
Topics: Affect; Anesthetics, Dissociative; Animals; Anti-Anxiety Agents; Anti-Dyskinesia Agents; Anxiety Disorders; Attitude; Behavior; Botulinum Toxins; Depressive Disorder; Facial Expression; Hallucinogens; Humans; Ketamine; Placebo Effect; Psilocybin; Treatment Outcome | 2013 |
Psychedelic drugs-a new era in
psychiatry?
.
Topics: Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychiatry | 2019 |
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
Topics: Animals; Brain; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mental Disorders; Mental Health; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Randomized Controlled Trials as Topic | 2021 |
Cluster headache: state of the art of pharmacological treatments and therapeutic perspectives.
Topics: Antibodies, Monoclonal; Botulinum Toxins, Type A; Capsaicin; Carbon Dioxide; Clinical Trials as Topic; Cluster Headache; Humans; Ketamine; Lysergic Acid Diethylamide; Oxazolidinones; Psilocybin; Receptors, Calcitonin Gene-Related Peptide; Somatostatin; Tryptamines | 2021 |
Use and abuse of dissociative and psychedelic drugs in adolescence.
Topics: Adolescent; Adult; Age Factors; Animals; Dextromethorphan; Female; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Male; N-Methyl-3,4-methylenedioxyamphetamine; Phencyclidine; Psilocybin; Risk-Taking; Substance-Related Disorders | 2021 |
Blinding and expectancy confounds in psychedelic randomized controlled trials.
Topics: Confounding Factors, Epidemiologic; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mental Disorders; Psilocybin; Randomized Controlled Trials as Topic; Research Design | 2021 |
Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Ketamine; Psilocybin | 2022 |
[Contribution of serotonin 5-HT
Topics: Antidepressive Agents; Depressive Disorder, Major; Hallucinations; Hallucinogens; Humans; Ketamine; Psilocybin; Receptor, Serotonin, 5-HT2A; Serotonin | 2023 |
Role of Psychedelics in Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Ketamine; Psilocybin | 2023 |
New Pharmacologic Approaches to the Treatment of Bipolar Depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Humans; Ketamine; Psilocybin; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Ketamine; Mice; Psilocybin; Receptors, N-Methyl-D-Aspartate | 2023 |
Topics: Escitalopram; Hallucinogens; Humans; Ketamine; Mental Disorders; Psilocybin | 2023 |
Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results.
Topics: Brain; Hallucinogens; Humans; Ketamine; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin | 2023 |
Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.
Topics: Antidepressive Agents; Depression; Hallucinogens; Ketamine; Psilocybin; Receptors, Metabotropic Glutamate; Scopolamine | 2023 |
The possible place for psychedelics in pharmacotherapy of mental disorders.
Topics: Antidepressive Agents; Hallucinogens; Humans; Ketamine; Mental Disorders; Psilocybin; Serotonin | 2023 |
3 trial(s) available for psilocybin and ketamine
| Article | Year |
|---|---|
Psychometric evaluation of the altered states of consciousness rating scale (OAV).
Topics: Adult; Cluster Analysis; Consciousness; Female; Humans; Ketamine; Male; Models, Theoretical; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychometrics; Reproducibility of Results; Surveys and Questionnaires | 2010 |
Decreased directed functional connectivity in the psychedelic state.
Topics: Adult; Anticonvulsants; Cerebral Cortex; Connectome; Female; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Magnetoencephalography; Male; Nerve Net; Psilocybin; Tiagabine; Young Adult | 2020 |
Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States.
Topics: Alprazolam; Female; Humans; Ketamine; Methamphetamine; Middle Aged; Psilocybin; Psychiatry; Psychotropic Drugs; Public Policy; United States | 2022 |
19 other study(ies) available for psilocybin and ketamine
| Article | Year |
|---|---|
Discriminative response control produced with hashish, tetrahydrocannabinols (delta 8-THC and delta 9-THC), and other drugs.
Topics: Amphetamine; Animals; Atropine; Avoidance Learning; Cannabis; Chlordiazepoxide; Chlorpromazine; Choice Behavior; Cocaine; Cues; Diazepam; Discrimination, Psychological; Dronabinol; Ketamine; Levallorphan; Male; Morphine; Pentobarbital; Phencyclidine; Physostigmine; Psilocybin; Rats; Scopolamine; Transfer, Psychology; Yohimbine | 1974 |
The hallucinogens and the inhalants.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; DOM 2,5-Dimethoxy-4-Methylamphetamine; Dronabinol; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mescaline; N,N-Dimethyltryptamine; Phencyclidine; Psilocybin; Solvents; Substance-Related Disorders | 1984 |
Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.
Topics: Administration, Oral; Adult; Cerebral Cortex; Contingent Negative Variation; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Infusions, Intravenous; Ketamine; Male; Psilocybin; Psychiatric Status Rating Scales; Psychoses, Substance-Induced; Receptor, Serotonin, 5-HT2A; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin | 2002 |
5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users.
Topics: Adult; Cross-Sectional Studies; Female; Hallucinogens; Humans; Incidence; Ketamine; Lysergic Acid Diethylamide; Male; N-Methyl-3,4-methylenedioxyamphetamine; Prevalence; Psilocybin; Substance-Related Disorders; United Kingdom | 2007 |
The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.
Topics: Adult; Double-Blind Method; Emotions; Evoked Potentials, Visual; Excitatory Amino Acid Antagonists; Facial Expression; Female; Hallucinogens; Humans; Ketamine; Male; Psilocybin; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Serotonin Receptor Agonists; Young Adult | 2013 |
Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders.
Topics: Amphetamine; Cannabis; Drug Users; Ethanol; Female; Humans; Ketamine; Male; Mental Disorders; Pilot Projects; Psilocybin; Psychiatry; Psychoses, Substance-Induced | 2013 |
Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.
Topics: Adult; Australia; Behavior, Addictive; Drug Users; Europe; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Male; N,N-Dimethyltryptamine; Prevalence; Psilocybin; Substance-Related Disorders; United Kingdom; United States; Young Adult | 2014 |
The fibrinolytic system: A new target for treatment of depression with psychedelics.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Fibrinolysin; Fibrinolysis; Hallucinogens; Humans; Inflammation; Ketamine; Models, Theoretical; Neuropeptides; Neuroserpin; Plasminogen Activator Inhibitor 1; Psilocybin; Receptor, Serotonin, 5-HT2A; Receptors, Urokinase Plasminogen Activator; Serpins; Tissue Plasminogen Activator; United States; Urokinase-Type Plasminogen Activator | 2017 |
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin.
Topics: Brain; Brain Mapping; Consciousness; Hallucinogens; Healthy Volunteers; Humans; Ketamine; Lysergic Acid Diethylamide; Magnetoencephalography; Psilocybin; Surveys and Questionnaires | 2017 |
Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats.
Topics: Animals; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Hallucinogens; Ketamine; Locomotion; Male; Maze Learning; Psilocybin; Rats; Rats, Wistar; Time Factors | 2018 |
Disruptive Psychopharmacology.
Topics: Consciousness; Humans; Ketamine; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychopharmacology; Psychotropic Drugs | 2019 |
Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
Topics: Adult; Brain Waves; Connectome; Excitatory Amino Acid Antagonists; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Machine Learning; Magnetoencephalography; Nerve Net; Psilocybin; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT2 Receptor Agonists | 2019 |
[Ketamine, psilocybin, and rapid acting antidepressant: new promise for psychiatry?]
Topics: Antidepressive Agents; Humans; Ketamine; Psilocybin; Psychiatry | 2021 |
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Evaluation, Preclinical; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Psilocybin; Serotonin 5-HT2 Receptor Agonists | 2021 |
Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats.
Topics: Animals; Antidepressive Agents; Cognition; Humans; Ketamine; Male; Psilocybin; Rats; Serotonin | 2022 |
Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; DNA; gamma-Aminobutyric Acid; Ketamine; Neurotransmitter Agents; Psilocybin; Rats; Receptors, Glutamate | 2022 |
Rapid-Response Treatments for Depression and Requests for Physician-Assisted Death: An Ethical Analysis.
Topics: Depression; Ethical Analysis; Female; Humans; Ketamine; Physicians; Psilocybin; Suicide, Assisted | 2022 |
Use of psychedelics in the Czech Republic: results of recent population surveys.
Topics: Adult; Cannabis; Cross-Sectional Studies; Czech Republic; Hallucinogens; Humans; Illicit Drugs; Ketamine; Lysergic Acid Diethylamide; Male; Psilocybin; Substance-Related Disorders | 2022 |
Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin.
Topics: Animals; Brain; Dorsal Raphe Nucleus; Female; Genes, Immediate-Early; Hallucinogens; Ketamine; Male; Mice; Proto-Oncogene Proteins c-fos; Psilocybin | 2023 |